GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » Book Value per Share

Immuneering (Immuneering) Book Value per Share : $2.66 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immuneering Book Value per Share?

Immuneering's book value per share for the quarter that ended in Mar. 2024 was $2.66.

During the past 12 months, Immuneering's average Book Value Per Share Growth Rate was -28.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Immuneering's current price is $1.4681. Its book value per share for the quarter that ended in Mar. 2024 was $2.66. Hence, today's PB Ratio of Immuneering is 0.55.

During the past 5 years, the highest P/B Ratio of Immuneering was 4.89. The lowest was 0.37. And the median was 1.65.


Immuneering Book Value per Share Historical Data

The historical data trend for Immuneering's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuneering Book Value per Share Chart

Immuneering Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
-0.76 -1.66 5.93 4.16 3.09

Immuneering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 3.93 3.55 3.09 2.66

Competitive Comparison of Immuneering's Book Value per Share

For the Biotechnology subindustry, Immuneering's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuneering's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuneering's PB Ratio distribution charts can be found below:

* The bar in red indicates where Immuneering's PB Ratio falls into.



Immuneering Book Value per Share Calculation

Immuneering's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(90.58-0.00)/29.27
=3.09

Immuneering's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(78.72-0.00)/29.65
=2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Immuneering  (NAS:IMRX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Immuneering Book Value per Share Related Terms

Thank you for viewing the detailed overview of Immuneering's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuneering (Immuneering) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Second Floor, Cambridge, MA, USA, 02142
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood officer: Chief Business Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld officer: Chief People Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales officer: Vice President, Finance C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall officer: Chief Scientific Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin officer: CFO, Treasurer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind director, 10 percent owner, officer: President and CEO C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett officer: Chief Medical Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman director 255 STATE STREET, BOSTON MA 02109